Dr. Gary S. Jacob, Chief Executive Officer of OKYO Pharma OKYO, was just recently a visitor on Benzinga’s All Gain access to.
OKYO Pharma is a biotechnology business concentrated on the therapy of eye conditions. OKYO is presently creating OK-101 to deal with completely dry eye condition, which is a presently underserved as well as unattended problem impacting numerous individuals in the united state. According to the business, the addressable market surpasses $5 billion.
OK-101 has simply had its First Person First Check out, noting the start of its stage 2 tests. The business is really thrilled concerning this occasion as well as claims it anticipates leading line information by the end of the year.
Enjoy the complete meeting below:
Included image by v2osk on Unsplash
This blog post includes funded marketing web content. This web content is for informative functions just as well as is not planned to be spending suggestions.
© 2023 Benzinga.com. Benzinga does not supply financial investment suggestions. All legal rights scheduled.
